

Appendix 3 Risk of Bias in included studies

Studies with low, moderate or high risk of Bias have been included in the report.
Studies with unacceptably high risk of bias have been excluded (Appendix 2).

Traffic light plot of risk of Bias in included studies [1-6].

Study	Risk of bias								Overall
	D1	D2	D3	D4	D5	D6	D7	D8	
Boucher 2015	!	—	+	!	!	!	—	!	!
Chen 2016	!	—	+	!	●	—	—	!	!
Fumagalli 2022	—	!	+	!	!	+	—	+	!
Kasapkara 2024	!	!	—	—	●	—	—	!	!
Pridjian 1994	!	●	+	!	●	!	—	+	!
VanRappard 2016	!	!	+	—	!	+	—	!	!

D1 = Domain 1; D2 = Domain 2; D3 = Domain 3; D4 = Domain 4; D5 = Domain 5; D6 = Domain 6; D7 = Domain 7; D8 = Domain 8

! = High; — = Moderate; + = Low; ● = Not applicabel

Risk of Bias domains:

- D1: Bias due to confounding
- D2: Bias in selection of participants into the study
- D3: Bias in classification of interventions
- D4: Bias due to deviations from intended interventions
- D5: Bias due to missing data
- D6: Bias in measurement of outcomes
- D7: Bias in selection of the reported result
- D8: Conflict of interests

Visualisations made using Robvis tool [7].

References

1. Boucher AA, Miller W, Shanley R, Ziegler R, Lund T, Raymond G, et al. Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. *Orphanet J Rare Dis*. 2015;10:94. Available from: <https://doi.org/10.1186/s13023-015-0313-y>
2. Chen X, Gill D, Shaw P, Ouvrier R, Troedson C. Outcome of Early Juvenile Onset Metachromatic Leukodystrophy After Unrelated Cord Blood Transplantation: A Case Series and Review of the Literature. *Journal of Child Neurology*. 2016;31(3):338-44. Available from: <https://doi.org/10.1177/0883073815595078>
3. Fumagalli F, Calbi V, Natali Sora MG, Sessa M, Baldoli C, Rancoita PMV, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. *Lancet*. 2022;399(10322):372-83. Available from: [https://doi.org/10.1016/s0140-6736\(21\)02017-1](https://doi.org/10.1016/s0140-6736(21)02017-1)
4. Kasapkara ÇS, CİVELEK ÜREY B, BİLGİNER GÜRBÜZ B, Küçükçongar Yavaş A, Keçeli AM, Öncül Ü, et al. Clinical and Radiological Profile of Nine Patients with Metachromatic Leukodystrophy. *Molecular Syndromology*. 2024.
5. Pridjian G, Humbert J, Willis J, Shapira E. Presymptomatic late-infantile metachromatic leukodystrophy treated with bone marrow transplantation. *The Journal of Pediatrics*. 1994;125(5, Part 1):755-8. Available from: [https://doi.org/10.1016/S0022-3476\(06\)80177-0](https://doi.org/10.1016/S0022-3476(06)80177-0)
6. van Rappard DF, Boelens JJ, van Egmond ME, Kuball J, van Hasselt PM, Oostrom KJ, et al. Efficacy of hematopoietic cell transplantation in metachromatic leukodystrophy: the Dutch experience. *Blood*. 2016;127(24):3098-101. Available from: <https://doi.org/10.1182/blood-2016-03-708479>
7. McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. *Research Synthesis Methods*. 2020;n/a(n/a). Available from: <https://doi.org/10.1002/jrsm.1411>